ANDAINTRAVENOUSPOWDER
Approved
Jul 2021
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
3
Mechanism of Action
accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK 1 ) receptors. Aprepitant has little or no affinity for serotonin (5-HT 3 ), dopamine, and corticosteroid receptors, the targets of existing…
Clinical Trials (3)
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Started Nov 2018
690 enrolled
Malignant Neoplasm
Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)
Started Sep 2012
1,015 enrolled
Chemotherapy-Induced Nausea and Vomiting (CINV)
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
Started Aug 2008
34 enrolled
Breakthrough Nausea and VomitingUnspecified Adult Solid Tumor, Protocol Specific